Firazyr Injection, Solution
Product Images NDC 54092-702

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Firazyr (NDC 54092-702). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Takeda Pharmaceuticals America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Firazyr 01)

Chemical structure diagram of icatibant acetate, the active ingredient in Firazyr injection, solution 30 mg/3 mL by Takeda Pharmaceuticals America, Inc. The diagram shows the molecular arrangement including peptide bonds and side chains characteristic of icatibant acetate.*

FDA Label Image

Figure 2 (Firazyr 02)

Kaplan-Meier survival curve comparing the proportion of patients not achieving a 50% reduction in symptoms over time from dose (hours) between Firazyr (icatibant acetate) and placebo groups. The solid line represents Firazyr (N=43) and the dashed line represents placebo (N=45), showing faster symptom reduction with Firazyr.*

FDA Label Image

Figure A (Firazyr 03)

Illustration showing a prefilled syringe labeled with plunger, syringe barrel, and protective cap over the syringe tip; a capped needle with needle cap, needle, and needle cap seal; and an alcohol wipe labeled with a note that it is not included in the carton.*

FDA Label Image

Figure B (Firazyr 04)

Instructional diagram showing a hand removing the outer packaging of a Firazyr (icatibant acetate) injection, solution, 30 mg/3 mL, subcutaneous. The image depicts the packaging box with the injection device inside and an arrow indicating how to pull open the outer wrap.*

FDA Label Image

Figure C (Firazyr 05)

An instructional illustration showing two hands preparing an injection. One hand is holding a vial or ampule while the other hand is about to break or open it, demonstrating the handling step prior to subcutaneous injection.*

FDA Label Image

Figure D (Firazyr 06)

An instructional diagram showing hands removing a needle cap from a syringe, indicating preparation of an injection. The illustration highlights the step of pulling the needle cap straight off the syringe before administration.*

FDA Label Image

Figure E (Firazyr 07)

An instructional illustration showing hands administering an injection subcutaneously. One hand is pinching the skin, and the other hand is holding a syringe, injecting at an angle with an arrow indicating a rotational motion of the syringe barrel.*

FDA Label Image

Figure F (Firazyr 08)

An anatomical diagram illustrating the recommended injection sites for subcutaneous administration. It shows the torso with two shaded square areas on the left and right sides of the lower back, indicating where the injection can be given.*

FDA Label Image

Figure G (Firazyr 09)

An instructional line drawing depicting the proper subcutaneous injection site in the abdominal area. The illustration shows a hand pinching the skin on the side of the abdomen, indicating where to administer an injection for the product Firazyr (icatibant acetate) injection solution.*

FDA Label Image

Figure H (Firazyr 10)

An instructional diagram showing a hand preparing to inject a syringe into another hand, demonstrating a subcutaneous injection technique.*

FDA Label Image

Figure I (Firazyr 11)

An illustration showing a hand holding a syringe prepared for injection. The drawing depicts the syringe with a plunger and a narrow needle tip, demonstrating how to grip the syringe properly, likely for subcutaneous administration.*

FDA Label Image

Figure J (Firazyr 12)

An instructional line drawing depicts a hand positioned near the abdomen, likely illustrating the subcutaneous injection site for Firazyr (icatibant acetate) injection, solution. The diagram focuses on the abdominal area and hand placement relevant for administration.*

FDA Label Image

Figure K (Firazyr 13)

An instructional diagram showing two methods of subcutaneous injection technique. One illustration depicts inserting the needle at a 45-degree angle into the skin, and the other at a 90-degree angle. Both demonstrate the angle of the syringe relative to the skin for proper injection.*

FDA Label Image

Figure L (Firazyr 14)

An instructional illustration showing a person administering a subcutaneous injection into the abdomen using a syringe. The image highlights the hand positioning and injection site for proper injection technique.*

FDA Label Image

Figure M (Firazyr 15)

An illustration showing a hand administering a subcutaneous injection into the forearm using a syringe. The injection needle is directed at the outer side of the forearm, with an arrow indicating the injection site. This image is likely instructional for subcutaneous injection technique.*

FDA Label Image

Figure N (Firazyr 16)

An instructional illustration showing a hand holding a syringe and administering a subcutaneous injection into the abdominal area, indicated by an arrow pointing to the injection site.*

FDA Label Image

Figure O (Firazyr 17)

An instructional illustration showing hands holding a syringe and a biohazard sharps disposal container. The syringe is positioned above the container, indicating proper disposal. The container is labeled with a biohazard symbol and the text 'DO NOT RECYCLE CONTAINS SHARPS.'*

FDA Label Image

Principal Display Panel (3 mL Syringe Carton)

Firazyr (icatibant injection) 30 mg/3 mL prefilled syringe packaging label by Takeda Pharmaceuticals America, Inc. This label indicates a single-dose prefilled syringe for subcutaneous injection, with 10 mg/mL concentration. It includes storage instructions, inactive ingredients, patient information references, a barcode, and contact details for the manufacturer.*

FDA Label Image

Principal Display Panel (3 Syringe Carton)

Firazyr (icatibant injection) 30 mg/3 mL prefilled syringe packaging label by Takeda Pharmaceuticals America, Inc. The carton contains three single-dose, prefilled syringes with 25G hypodermic needles. The label includes storage instructions and inactive ingredients, and notes the product is for subcutaneous injection only.*

FDA Label Image

Principal Display Panel (3 mL Syringe Carton)

Packaging label for Firazyr (icatibant injection) 30 mg/3 mL prefilled syringe for subcutaneous use. The label states it is a single-dose prefilled syringe with one 25G hypodermic needle included. Distributed by Takeda Pharmaceuticals America, Inc., the label includes storage instructions and a contact phone number.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.